Analysts Anticipate Genprex Inc (NASDAQ:GNPX) Will Post Earnings of -$0.22 Per Share
Analysts predict that Genprex Inc (NASDAQ:GNPX) will report ($0.22) earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have made estimates for Genprex’s earnings. Genprex reported earnings of ($0.15) per share in the same quarter last year, which indicates a negative year over year growth rate of 46.7%. The company is scheduled to announce its next quarterly earnings report on Tuesday, November 19th.
On average, analysts expect that Genprex will report full-year earnings of ($0.87) per share for the current fiscal year. Zacks’ EPS calculations are an average based on a survey of research analysts that cover Genprex.
Genprex (NASDAQ:GNPX) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03).
An institutional investor recently bought a new position in Genprex stock. Citadel Advisors LLC acquired a new position in shares of Genprex Inc (NASDAQ:GNPX) in the 2nd quarter, according to its most recent 13F filing with the SEC. The fund acquired 31,529 shares of the company’s stock, valued at approximately $39,000. Citadel Advisors LLC owned about 0.20% of Genprex at the end of the most recent reporting period. Institutional investors and hedge funds own 5.17% of the company’s stock.
Shares of Genprex stock traded down $0.06 during trading on Friday, hitting $0.87. 31,800 shares of the company were exchanged, compared to its average volume of 42,071. Genprex has a fifty-two week low of $0.64 and a fifty-two week high of $2.56. The stock has a market capitalization of $13.78 million, a price-to-earnings ratio of -0.97 and a beta of 1.44. The firm has a 50 day moving average price of $0.92 and a 200 day moving average price of $1.40.
Genprex Company Profile
Genprex, Inc operates as a clinical-stage gene therapy company. It engages in developing a new approach for treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells, and modulates the immune response against cancer cells.
Further Reading: How analysts view the yield curve
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Genprex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genprex and related companies with MarketBeat.com's FREE daily email newsletter.